Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ociperlimab + tislelizumab versus pembrolizumab in previously untreated PD-L1-high advanced NSCLC, with a Japanese safety run-in
jRCT2061210035Phase 3Completed
- Sponsor
- BeOne Medicines
- Start
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of ociperlimab in non-small cell lung cancer (NSCLC) and Nonhematologic neoplasms (4 arms), sponsored by BeOne Medicines. Primary endpoints: Safety and tolerability, Pharmacokinetics of ociperlimab and 1 more. Started Nov 2021; status: completed.
02
Drugs
ociperlimab
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2061210035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061210035.